# Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

Source: https://onco.cc/trials/nct04557449/  
OnCo record `nct04557449` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Atirmociclib, Letrozole, Fulvestrant in prostate cancer, run by Pfizer, active and no longer recruiting.

## Summary

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors is a phase 2 interventional study registered as NCT04557449 by Pfizer, with 362 participants enrolled, started 2020-09-23 and due to reach its primary completion in 2026-09-23. Interventions recorded: PF-07220060, Letrozole, Fulvestrant, Midazolam, Enzalutamide. Conditions listed: Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04557449
- Phase: 2
- Setting: A PHASE 1/2A STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
- Sponsor: Pfizer
- Enrolled: 362

## Sources

- ClinicalTrials.gov NCT04557449: https://clinicaltrials.gov/study/NCT04557449

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Atirmociclib](https://onco.cc/drugs/atirmociclib/), [Enzalutamide](https://onco.cc/drugs/enzalutamide/), [Fulvestrant](https://onco.cc/drugs/fulvestrant/), [Letrozole (and other aromatase inhibitors)](https://onco.cc/drugs/letrozole/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct04557449.json